Quest For Growth

Confo Therapeutics is a drug discovery company based in Brussels, Belgium, founded in 2015. The company focuses on developing internal drug discovery programs centered on G-protein coupled receptors (GPCRs), which are critical targets for therapeutic intervention. Utilizing its proprietary CONFO technology, Confo Therapeutics stabilizes active-state conformations of GPCRs, enabling researchers to access previously unreachable structural features. This innovation facilitates the discovery of novel agonists, addressing unmet medical needs and potentially leading to improved treatments in the medical field. The company aims to build a robust portfolio of drug discovery programs, leveraging its unique approach to enhance therapeutic options.

Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, providing comprehensive tracking solutions directly from the cloud. Established in 2013 and based in Ghent, Belgium, the company offers a range of low-power, context-aware sensing technologies, including its STICKNTRACK product line. Sensolus combines hardware GPS trackers with a fully integrated cloud application, enabling users to manage and monitor their assets with ease. The company serves various industries, including manufacturing, waste management, cargo transport, logistics, and automotive, focusing on delivering real-time information and maintenance-free asset tracking solutions.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Miracor Medical is a medical device company focused on developing and commercializing innovative technologies for treating severe cardiac diseases. Established in 2008 and headquartered in Awans, Belgium, the company specializes in the PiCSO Impulse System, which utilizes pressure-controlled intermittent coronary sinus occlusion. This system is designed to aid cardiac surgeons in treating patients who have experienced myocardial infarction, particularly those undergoing coronary artery bypass grafting surgery. The PiCSO treatment aims to enhance microvascular perfusion and improve cardiac function by increasing blood flow to damaged heart tissue, potentially reducing the risk of heart failure following acute myocardial infarction.

Sensolus NV specializes in the design and development of GPS trackers for non-powered assets, providing comprehensive tracking solutions directly from the cloud. Established in 2013 and based in Ghent, Belgium, the company offers a range of low-power, context-aware sensing technologies, including its STICKNTRACK product line. Sensolus combines hardware GPS trackers with a fully integrated cloud application, enabling users to manage and monitor their assets with ease. The company serves various industries, including manufacturing, waste management, cargo transport, logistics, and automotive, focusing on delivering real-time information and maintenance-free asset tracking solutions.

iNEWiT is an engineering company based in Mechelen, Belgium, founded in 2005. The company specializes in identifying, designing, and creating applications and devices for the mobile market. It develops mobile video communication applications and offers a range of wireless communication technologies, including GPRS/EDGE, 3G, HSDPA/HSUPA, WiFi, WiMAX, and satellite networks. iNEWiT's products utilize patent-pending technology to transmit data, video, and sound across various wireless and wired environments and platforms. Additionally, the company provides plug-and-play products tailored for the business-to-consumer markets.

Movetis NV is a pharmaceutical company dedicated to the discovery, development, and commercialization of drugs targeting gastrointestinal (GI) disorders. The company addresses a range of conditions, including severe chronic constipation, ascites, and pediatric reflux, as well as severe GI motility disorders like refractory gastro-oesophageal reflux disease. Its lead product, Resolor, is specifically designed for the symptomatic treatment of chronic constipation in women, with ongoing research for its efficacy in males and children, as well as in cases of opioid-induced constipation and post-operative ileus. Movetis is also developing M0002, currently in Phase II trials for treating ascites, and M0003, which is set to enter Phase II development for symptomatic relief of heartburn and regurgitation in patients unresponsive to proton pump inhibitors. Additionally, the company has two prioritized compounds from its preclinical portfolio and maintains partnerships with universities in Ghent, Leuven, and Rotterdam. Founded in 2006, Movetis is based in Turnhout, Belgium.

Gemidis is a spin-off company from Ghent University (Belgium) and IMEC (Belgium) and was officially founded in August 2004. Gemidis develops, produces and sells LCOS imagers and driver electronics for both consumer and professional markets.